路透1月13日 - 默克MRK.N周一表示，该公司已上调了对新增长动力的展望，预计到2030年代中期，这些新业务将带来700亿 美元的收入，因为该公司在其重磅癌症疗法Keytruda面临迫在眉睫的竞争之前，将加快推出更多药物。
这家制药商现在预计，心脏代谢和呼吸系统治疗药物将带来约 200 亿美元的销售额，高于之前预计的 150 亿美元；而传染病药物预计将贡献约 150 亿美元，此前估计为 50 亿美元。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.